Literature DB >> 16033853

Fibroblast growth factor 23: roles in health and disease.

Erik A Imel1, Michael J Econs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16033853     DOI： 10.1681/ASN.2005050573

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  32 in total

Review 1.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

2.  Diffuse pain, hypophosphatemia, and a subcutaneous nodule.

Authors:  Christine A Dewitt; Michael T Collins; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2007-09       Impact factor: 11.527

Review 3.  Does FGF23 toxicity influence the outcome of chronic kidney disease?

Authors:  Mohammed Shawkat Razzaque
Journal:  Nephrol Dial Transplant       Date:  2008-11-07       Impact factor: 5.992

4.  Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.

Authors:  Thomas O Carpenter; Erik A Imel; Mary D Ruppe; Thomas J Weber; Mark A Klausner; Margaret M Wooddell; Tetsuyoshi Kawakami; Takahiro Ito; Xiaoping Zhang; Jeffrey Humphrey; Karl L Insogna; Munro Peacock
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

Review 5.  Inherited Arterial Calcification Syndromes: Etiologies and Treatment Concepts.

Authors:  Yvonne Nitschke; Frank Rutsch
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

6.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

Authors:  Shoji Ichikawa; Erik A Imel; Mary L Kreiter; Xijie Yu; Donald S Mackenzie; Andrea H Sorenson; Regina Goetz; Moosa Mohammadi; Kenneth E White; Michael J Econs
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.

Authors:  Erik A Imel; Xiaoping Zhang; Mary D Ruppe; Thomas J Weber; Mark A Klausner; Takahiro Ito; Maria Vergeire; Jeffrey S Humphrey; Francis H Glorieux; Anthony A Portale; Karl Insogna; Munro Peacock; Thomas O Carpenter
Journal:  J Clin Endocrinol Metab       Date:  2015-04-28       Impact factor: 5.958

8.  Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.

Authors:  Regina Goetz; Yuji Nakada; Ming Chang Hu; Hiroshi Kurosu; Lei Wang; Teruyo Nakatani; Mingjun Shi; Anna V Eliseenkova; Mohammed S Razzaque; Orson W Moe; Makoto Kuro-o; Moosa Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

Review 9.  Post-renal transplantation hypophosphatemia.

Authors:  Khashayar Sakhaee
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

10.  Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.

Authors:  Shoji Ichikawa; Andrea H Sorenson; Anthony M Austin; Donald S Mackenzie; Timothy A Fritz; Akira Moh; Siu L Hui; Michael J Econs
Journal:  Endocrinology       Date:  2009-02-12       Impact factor: 4.736
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.